,

Prescient Therapeutics chooses three cancer programs for its next-generation CAR T platform

January 19, 2021

Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer acute myeloid leukemia (AML); solid tumours including breast, ovarian and gastric cancers; and glioblastoma multiforme, the aggressive brain cancer.

Prescient’s OmniCAR technology represents a step up from the current chimeric antigen receptor T-cell (CAR T) therapy, a form of immunotherapy that involves modifying a patient’s white blood cells so they recognise and kill cancer cells.

An American woman, Laurie Adami, recently told Stockhead how CAR T therapy saved her life by curing her stage IV follicular non-Hodgkin lymphoma.

Related Post

This investor centre was built by Reach Markets

©2022 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.